Influence of tumor peroxisome proliferator-activated receptor gamma and delta expression on postoperative mortality of patients undergoing colorectal cancer surgery.
To evaluate the influence of peroxisome proliferator-activated receptor gamma (PPAR gamma) and delta (PPAR delta) expression on postoperative mortality of patients with colorectal cancer (CRC). Optimal cutoff values were determined for each relative expression ratio (RER) (RER = PPAR expression of tumor/PPAR expression of normal mucosa) of PPAR, and patients were divided into two groups as follows (PPAR staging): patients with elevated RERs of PPAR gamma (> 2.0) or PPAR delta (> 1.0) were termed Group H, and patients showing none of these elevated RERs of PPARs were termed Group L. Prognostic significance was analyzed by univariate and Kaplan-Meier analyses. In total, 26 CRC patients were studied. Univariate analysis revealed that PPAR gamma (> 2.0/ < or = 2.0) (odds ratio, 11.43; 95% C.I., 1.154-113.1; p = .0373), PPAR delta (> 1.0/ < or = 1.0) (odds ratio, 15.00; 95% C.I., 1.503-149.7; p = .0210) and PPAR staging (H/L) (odds ratio, 63.00; 95% C.I., 4.956-800.8; p = .0014) were significant predictors of postoperative mortality. Kaplan-Meier analysis revealed that the survival curve of patients with CRC was clearly divided by PPAR staging (log rank test, p <.0001). Evaluation of PPAR gamma and delta expression is useful for predicting postoperative mortality in patients undergoing CRC surgery.